第23回あわじ感染と免疫国際フォーラム

○Shara Bakytbek^1,2,3, Farzaneh Valanezhad^1,2,3, Ayako Hyuga^1,2,3, Shin-Ichi Inoue^2,4, Yui Katsuyuki⁵, Shusaku Mizukami^3,6, Risa Nakamura^1,2,3, Haruka Abe¹¹, Futoshi Hasebe^2,11, Kazuhide Onoguchi⁷, Sebastian Kapell^8,9, Kouichi Morita^3,10, Shinjiro Hamano^1,2,3 (1. Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki (Japan), 2. Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki (Japan), 3. The Vaccine Research and Development Center, DEJIMA Infectious Disease Research Alliance (DIDA), Nagasaki University, Nagasaki (Japan), 4. Department of Molecular Microbiology and Immunology, Division of Immunology, Nagasaki University, Nagasaki (Japan), 5. SHIONOGI Global Infectious Diseases Division Institute of Tropical Medicine, Nagasaki University, Nagasaki (Japan), 6. Department of Immune Regulations, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 7. AI Drug Development Division, NEC Corporation, Tokyo (Japan), 8. Department of Vaccine Informatics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 9. NEC OncoImmunity AS, Ullernchausseen 64/66, 0379, Oslo (Norway), 10. Department of Virology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 11. Vietnam Research Station, center for Infectious Disease Research in Asia and Africa, Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan))

○Farzaneh Valanezhad¹, Jalal Alshaweesh², Shara Bakytbek¹, Sakiko Shimizu³, Ryo Tanaka³, Yoichiro Iwase³, Risa Nakamura¹, Greg Matlashewski⁴, Sreenivas Gannavaram⁵, Hira Nakhasi⁵, Abhay Satoskar⁶, Shinjiro Hamano¹ (1. 1-Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan (Japan), 2. 4-The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Japan (Japan), 3. 5-TERUMO Corporation, Medical Care Solutions Company, Pharmaceutical Solutions Division, R&D, Japan (Japan), 4. 6-Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada (Canada), 5. 7-Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993 US (United States of America), 6. 8-Department of Pathology, The Ohio State University, Columbus, Ohio, US (United States of America))

○Jordan Villa¹, Taishi Onodera², Saya Moriyama², Ayumi Kitano², Yoshimasa Takahashi², Kazuo Yamashita¹ (1. KOTAI Biotechnologies, Inc (Japan), 2. Research Center for Vaccine Development, National Institute of Infectious Diseases (NIID) (Japan))

○Sebastian Kapell^1,2, Shara Bakytbek^4,6, Jean Claude Balingit⁶, Farzaneh Valanezhad^4,6, Ayako Hyuga^4,6, Shin-Ichi Inoue⁸, Yui Katsuyuki⁸, Shusaku Mizukami^5,6, Shinjiro Hamano^4,6, Matheus Ferraz², Ioannis Vardaxis², Daiki Miura³, Daiki Mori³, Kazuhide Onoguchi³, Kaidre Bendjama^1,2, Basu Dev Pandey¹⁰, Corazon Cerilla Buerano⁷, Trevor Clancy, Satoshi Kaneko^6,9, Kouichi Morita^6,7 (1. Dept. of Vacc. Inform., Inst. of Trop. Med., Nagasaki Univ. (Japan), 2. NEC Oncoimmunity AS (Norway), 3. NEC Corporation (Japan), 4. Dept. Parasitol., Inst. Trop. Med., Nagasaki Univ. (Japan), 5. Dept. of Immun. Regul., Inst. of Trop. Med., Nagasaki Univ. (Japan), 6. Vaccine Research and Development Center Infectious Disease Research Alliance (DEJIMA), Nagasaki Univ. (Japan), 7. Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine Nagasaki Uni. (Japan), 8. Dept. of Immunol., Grad. Sch. of Biomed. Sci., Nagasaki Univ. (Japan), 9. Dept. of Eco-epidemiol., Inst. of Trop. Med., Nagasaki Univ. (Japan), 10. Dept. of Mol. Epi., Inst. of Trop., Med., Nagasaki Univ. (Japan))